These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2114986)
21. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia. Schonfeld G; Aguilar-Salina C; Elias N Am J Cardiol; 1998 Feb; 81(4A):43B-46B. PubMed ID: 9526813 [TBL] [Abstract][Full Text] [Related]
22. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. Everson GT; McKinley C; Kern F J Clin Invest; 1991 Jan; 87(1):237-46. PubMed ID: 1845870 [TBL] [Abstract][Full Text] [Related]
23. Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia. Barlow CW; Soicher ER; Jankelow D; Myburgh DP S Afr Med J; 1990 May; 77(10):504-5. PubMed ID: 2343347 [TBL] [Abstract][Full Text] [Related]
24. Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients. Effects on biliary lipid metabolism during weight maintenance and weight reduction. Mazzella G; Bazzoli F; Festi D; Ronchi M; Aldini R; Roda A; Grigolo B; Simoni P; Villanova N; Roda E Gastroenterology; 1991 Aug; 101(2):490-6. PubMed ID: 2065925 [TBL] [Abstract][Full Text] [Related]
25. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia. Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725 [TBL] [Abstract][Full Text] [Related]
26. Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia. Otto C; Parhofer KG; Ritter MM; Richter WO; Schwandt P Br J Clin Pharmacol; 1998 Nov; 46(5):473-8. PubMed ID: 9833601 [TBL] [Abstract][Full Text] [Related]
28. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Arca M; Natoli S; Micheletta F; Riggi S; Di Angelantonio E; Montali A; Antonini TM; Antonini R; Diczfalusy U; Iuliano L Free Radic Biol Med; 2007 Mar; 42(5):698-705. PubMed ID: 17291993 [TBL] [Abstract][Full Text] [Related]
29. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526 [TBL] [Abstract][Full Text] [Related]
30. The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS). Grundy SM; Lan SP; Lachin J J Clin Invest; 1984 Apr; 73(4):1156-66. PubMed ID: 6368591 [TBL] [Abstract][Full Text] [Related]
31. Serum and bile lipids in young women with radiolucent gallstones. Cavallini A; Messa C; Mangini V; Argese V; Misciagna G; Giorgio I Am J Gastroenterol; 1987 Dec; 82(12):1279-82. PubMed ID: 3687905 [TBL] [Abstract][Full Text] [Related]
32. Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment. Arca M; Cambuli VM; Montali A; Sentinelli F; Filippi E; Campagna F; Quagliarini F; Antonini R; Romeo S; Baroni MG Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):660-6. PubMed ID: 19632099 [TBL] [Abstract][Full Text] [Related]
33. The cholesterol saturation of bile and its reduction by chenodeoxycholic acid in massively obese patients. Whiting MJ; Hall JC; Iannos J; Roberts HG; Watts JM Int J Obes; 1984; 8(6):681-8. PubMed ID: 6533091 [TBL] [Abstract][Full Text] [Related]
34. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. O'Kane MJ; Trinick TR; Tynan MB; Trimble ER; Nicholls DP Br J Clin Pharmacol; 1992 Apr; 33(4):451-3. PubMed ID: 1576071 [TBL] [Abstract][Full Text] [Related]
35. [Effect of omega-3-fatty acids on biliary lipids and lithogenicity]. Wechsler JG; Swobodnik W; Wenzel H; Saal D; Janowitz P; Ditschuneit H Z Gastroenterol; 1989 May; 27(5):254-7. PubMed ID: 2756729 [TBL] [Abstract][Full Text] [Related]
36. Speed of change in biliary lipids and bile acids with chenodeoxycholic acid--is intermittent therapy feasible? Iser JH; Murphy GM; Dowling RH Gut; 1977 Jan; 18(1):7-15. PubMed ID: 838406 [TBL] [Abstract][Full Text] [Related]
37. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Calabresi L; Donati D; Pazzucconi F; Sirtori CR; Franceschini G Atherosclerosis; 2000 Feb; 148(2):387-96. PubMed ID: 10657575 [TBL] [Abstract][Full Text] [Related]
38. Biliary lipid secretion, bile acid metabolism, and gallstone formation are not impaired in hepatic lipase-deficient mice. Amigo L; Mardones P; Ferrada C; Zanlungo S; Nervi F; Miquel JF; Rigotti A Hepatology; 2003 Sep; 38(3):726-34. PubMed ID: 12939599 [TBL] [Abstract][Full Text] [Related]
39. Biliary lipid composition in normo- and hyperlipoproteinemia. Ahlberg J; Angelin B; Einarsson K; Hellström K; Leijd B Gastroenterology; 1980 Jul; 79(1):90-4. PubMed ID: 7380228 [TBL] [Abstract][Full Text] [Related]
40. Physical activity, biliary lipids, and gallstones in obese subjects. Chuang CZ; Martin LF; LeGardeur BY; Lopez A Am J Gastroenterol; 2001 Jun; 96(6):1860-5. PubMed ID: 11419840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]